-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Outlook Therapeutics to Neutral, Announces $1 Price Target

Benzinga·08/29/2025 12:47:27
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral and announces $1 price target.